Top ASCO GU 2026 Takeaways for Nurses and APPs

The 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium featured several high-impact studies detailing therapeutic advancements and patient-reported outcomes (PROs) across bladder, renal, and prostate cancers. For oncology nurses and advanced practice providers (APPs), these findings provide essential data on new treatment combinations, evolving safety profiles, and the long-term impact of therapy on patient quality of life (QOL).